Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 168, Issue 1, pp 92–94 | Cite as

Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate

  • M. V. Filimonova
  • T. S. PodosinnikovaEmail author
  • A. S. Samsonova
  • V. M. Makarchuk
  • L. I. Shevchenko
  • A. S. Filimonov
ONCOLOGY
  • 2 Downloads

Combined chronic treatment of Ehrlich solid carcinoma (EC) with an NOS inhibitor 1-isobutanoyl-2-isopropylisothiourea hydrobromide (T1023) and a PDK1 inhibitor dichloroacetate was accompanied by statistically significant synergetic antitumor effects manifested in a significant and stable suppression of neoplasm growth (by 55-65%). Separate treatment with T1023 and dichloroacetate induced moderate short-term inhibition of tumor growth (by 30-35%) followed by weakening of tumor sensitivity to these substances. These results attest to synergetic antitumor effects NOS inhibitor T1023 and PDK1 inhibitor dichloroacetate producing antiangiogenic and hypoxia-targeted cytotoxic effects, during their combined administration, which allows overcoming the adaptive potential of the tumors.

Key Words

NOS inhibitors PDK1 inhibitor Ehrlich carcinoma hypoxic resistance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kaprin AD, Galkin VN, Zhavoronkov LP, Ivanov VK, Ivanov SA, Romanko YuS. Synthesis of basic and applied research is the basis of obtaining high-quality findings and translating them into clinical practice. Radiatsiya Risk. 2017;26(2):26-40. Russian.CrossRefGoogle Scholar
  2. 2.
    Koblyakov VA. Hypoxic state and glycolysis as a possible anticancer therapeutic target. Uspekhi Mol. Onkol. 2014;1(2):44-49. Russian.Google Scholar
  3. 3.
    Osinskii S, Vaupel P. Microphysiology of Tumors. Kiev, 2009. Russian.Google Scholar
  4. 4.
    Filimononva MV, Shevchenko LI, Yuzhakov VV, Marchuk VM, Lushnikova GA. Experimental and theoretical designing of new-generation anti-shock and antitumor agents based on NO-synthase inhibitors. Proceedings of the Regional Competition of Basic Research Projects. Kaluga, 2014. Vol. 19. P. 151-155. Russian.Google Scholar
  5. 5.
    Filimonova MV, Yuzhakov VV, Shevchenko LI, Bandurko LN, Sevankaeva LE, Makarchuk VM, Chesnakova EA, Shevchuk AS, Tsyganova MG, Fomina NK, Ingel IE, Surinova VI. Experimental study of antitumor activity of new nitric oxide synthase inhibitor T1023. Mol. Med. 2015;(1):61-64. Russian.Google Scholar
  6. 6.
    Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer. 2008;8(8):592-603.CrossRefGoogle Scholar
  7. 7.
    Duan Y, Zhao X, Ren W, Wang X, Yu KF, Li D, Zhang X, Zhang Q. Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation. Onco Targets Ther. 2013;6:189-198.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Pyaskovskaya ON, Boychuk IV, Fedorchuk AG, Kolesnik DL, Dasyukevich OI, Solyanik GI. Aconitine-containing agent enhances antitumor activity of dichloroacetate against Ehrlich carcinoma. Exp. Oncol. 2015;37(3):192-196.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • M. V. Filimonova
    • 1
  • T. S. Podosinnikova
    • 1
    Email author
  • A. S. Samsonova
    • 1
  • V. M. Makarchuk
    • 1
  • L. I. Shevchenko
    • 1
  • A. S. Filimonov
    • 1
  1. 1.A. F. Tsyb Medical Radiological Research Center, Branch of the National Medical Research Center of RadiologyMinistry of Health of the Russian FederationObninskRussia

Personalised recommendations